EGFR and non-small cell lung carcinoma: In recent years, liquid biopsy has obtained a place in standard clinical care for its role in selection of patients for third generation tyrosine kinase inhibitors in EGFR-mutant NSCLC after progression on first/second generation treatment, by detection of the p.T790M mutation [32].